PCRX — Pacira Biosciences Share News
0.000.00%
Last trade - 00:00- $878.64m
- $1.04bn
- $726.41m
Brief: Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Pacira Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization As A Meaningful Step To Enhance Value For Shareholders
Brief: Pacira Biosciences Inc - Authorizes $300 Million Share Repurchase Program
Brief: Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule
Pacira secures pain drug patent deal until 2030; shares up
Brief: Pacira Biosciences Announces Settlement Of U.S. Patent Litigation For Exparel
Brief: Pacira Biosciences Announces First Patient Dosed In Phase 2 Study Evaluating Safety And Efficacy Of Pcrx-201 For The Treatment Of Osteoarthritis Of The Knee
Brief: Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual
Pacira Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Pacira Biosciences FY Adjusted EBITDA USD 224 Million Vs. IBES Estimate USD 222 Million
J.P. Morgan raises Pacira Biosciences PT on delayed generic competition for pain drug
U.S. RESEARCH ROUNDUP-AmEx, Elevance Health, SouthState
Brief: Pacira Biosciences Strengthens Executive Leadership Team
Brief: Pacira Biosciences Sees Double-Digit Compounded Annual Growth Rate In Product Revenue By 2030
Brief: Pacira Biosciences Receives FDA 510K Clearance For New Iovera° Smarttip To Manage Chronic Low Back Pain Via Long-Lasting Medial Branch Nerve Block
Brief: Doma Perpetual Capital Management Intends To Nominate Four Highly Qualified, Independent Director Candidates At 2025 Annual Meeting Of Pacira Biosciences
Brief: Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Pacira Awarded New U.S. Patent Covering EXPAREL Composition